Latest from Joseph Haas
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.
Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.
Seeking to bring its psychedelic candidate to market in treatment-resistant depression, Ireland’s GH sees its drug-device inhalation combo product as offering strong differentiation versus Spravato.
Expectations for Skyrizi, Rinvoq skyrocket, and while AbbVie expects to return to compound annual growth in the high single digits this year, the Medicare drug benefit redesign will cut revenue by about 4%.
The Phase III HYPERION study in recently diagnosed PAH is ending early due to sotatercept’s strength. Phase III ZENITH similarly stopped early in November.
Backed by Versant Ventures, Helicore will pursue optimized therapy for underserved obesity patients with an antibody that directly antagonizes GIP and plans for antibody conjugate therapies.